The controversy began with a series of three studies pointing to ITSN1 as a Parkinson’s disease susceptibility gene. Loss-of-function variants are mutations that disable a gene’s protein product, and when such variants occur in ITSN1, the resulting condition is predicted to be haploinsufficiency: having only one working copy of the gene is not enough for normal cellular function. The most recent and most compelling piece of evidence came from Ganoza and colleagues, who screened the Rostock International Parkinson’s Disease study, known as ROPAD, a cohort that includes 8,660 participants with Parkinson’s disease. Their analysis globally replicated the earlier findings and established that ITSN1 loss-of-function carriers represent roughly one to two individuals per thousand with Parkinson’s disease suspected of having a genetic cause.

The scale of the risk elevation is what makes ITSN1 so remarkable. According to the reply, a carrier of an ITSN1 loss-of-function variant faces between five and fifteen times the risk of developing Parkinson’s disease compared with a non-carrier. That places ITSN1 among the strongest genetic risk factors identified for the condition, in a category typically reserved for well-known genes such as LRRK2 and GBA1. Equally notable is the clinical picture: the Parkinson’s disease that emerges in ITSN1 carriers does not differ significantly from classical, non-genetic Parkinson’s disease, meaning carriers present with the familiar motor syndrome rather than an exotic or easily distinguishable variant of the illness.

The Paris team had approached the gene from a different angle. After identifying three pedigrees with ITSN1 loss-of-function variants in their own cohort at the Paris Brain Institute, two of which showed positive segregation of the variant with disease across generations, they hypothesized that ITSN1 might act as a Mendelian gene. In genetics, a Mendelian gene is one in which a single mutation is sufficient to cause disease in a predictable inheritance pattern, typically autosomal dominant or recessive, as opposed to risk genes that merely shift probabilities. If ITSN1 were Mendelian, families carrying one mutation would show the disease appearing in multiple relatives in an orderly pattern, and genetic counseling would follow established rules for dominant disorders.

Ganoza and colleagues tested this hypothesis using the ROPAD data and found it wanting. The frequency of positive family history among ITSN1-associated Parkinson’s disease individuals did not differ significantly from that of individuals without ITSN1 loss-of-function variants: 23 percent versus 34 percent, a difference that failed to reach statistical significance with a p-value of 0.5. On its face, this argues against a straightforward Mendelian model, since a true dominant gene should produce a conspicuously elevated rate of affected relatives. But the Paris group, in their reply, argues that the comparison is less conclusive than it appears, and they raise two methodological concerns that deserve careful attention from anyone following the genetics of neurodegenerative disease.

The first concern involves the composition of the ROPAD cohort itself. The Paris researchers noticed that the frequency of positive family history among non-carriers, 34 percent, seems higher than what would be expected for classical Parkinson’s disease in the general population. The likely explanation, they suggest, is recruitment bias: the cohort was enriched for individuals already suspected of having a genetic etiology for their disease. The authors of the original analysis acknowledged as much, noting that the early average age at onset in their cohort, 55 years, supports the presence of such a bias. Age at onset is a classic marker in Parkinson’s genetics, since earlier-onset disease is more often genetically driven, and a cohort selected for early onset will naturally over-represent familial cases on both sides of any genetic comparison.

The second concern is more fundamental: the ROPAD analysis did not provide pedigrees, or familial structures, for the 13 individuals carrying ITSN1 loss-of-function variants. Without those family trees, the field cannot know how many relatives were actually affected in individuals reporting a positive family history, whether the inheritance pattern suggested autosomal dominance or recessivity, or whether segregation analysis was performed to confirm that the variant tracked with disease. The Paris team offers a plausible alternative explanation for the negative result: several of the loss-of-function variants may have arisen de novo, meaning spontaneously in the carrier rather than being inherited, which would explain why family history was not always positive. There is also growing evidence of reduced penetrance for ITSN1, meaning that not everyone who carries a damaging variant develops disease. Sorting out these possibilities, the reply argues, will be essential before any conclusion can be drawn about the Mendelian hypothesis, and before accurate genetic counseling can be offered to carriers and their relatives.

The counseling challenge is compounded by a feature that makes ITSN1 genuinely unusual among Parkinson’s genes. Loss-of-function variants in ITSN1 are associated not only with Parkinson’s disease but also with neurodevelopmental disorders, conditions that manifest in infancy or childhood. Other recently discovered genes, such as PSMF1 and EPG5, similarly produce a clinical spectrum running from early-onset neurodevelopmental disorders to later-onset Parkinsonism, but in those cases the type of variant usually differs, with truncating variants producing more severe phenotypic consequences than missense variants, which change only a single amino acid. For ITSN1, by contrast, only loss-of-function variants have been reported in Parkinson’s disease, and all are predicted to cause haploinsufficiency. That raises a puzzle the reply states plainly: why could the same mechanism, the loss of one functional copy of the gene, lead to two such distinct phenotypes, a childhood neurodevelopmental disorder in some carriers and a late-life neurodegenerative disease in others?

One hypothesis involves the protein itself. Two isoforms of the ITSN1 protein product, Intersectin-1, are currently known, and the location of a loss-of-function variant, whether it disrupts one isoform or both, could in principle explain the variable expressivity. However, the reply notes that variants identified in both diseases appear to affect both isoforms, so this explanation alone does not suffice, and, as Ganoza and colleagues hypothesized, other modifying factors remain to be discovered. The Paris team sketches several research strategies to find them. Functional studies using biological materials from ITSN1 loss-of-function carriers are already underway to clarify why the loss of Intersectin-1 predisposes to Parkinson’s disease, a question that persists even though the protein’s many roles, particularly as a scaffold for membrane-associated processes such as endocytosis, have been extensively characterized. A second approach would leverage large Parkinson’s disease datasets to compare genetic variant frequencies, environmental exposures, and lifestyle habits between unaffected elderly controls and carriers, with particular attention to ITSN2, the gene encoding the second member of the intersectin family, whose protein can compensate for some defects caused by reduced ITSN1 expression. The consistency of the average age at onset across studies should help researchers choose an appropriate inclusion age for controls. Beyond loss-of-function variants, certain missense variants in the missense-constrained region of the gene, spanning amino acids 1199 to 1722, have been linked to neurodevelopmental disorders, and their possible role in Parkinson’s disease has not yet been explored.

Why does this academic debate matter beyond the laboratory? The reply closes with a warning about clinical practice. Genetic testing is becoming more accessible, and ITSN1 loss-of-function variants are not so rare, so they will increasingly surface as incidental findings in people tested for unrelated reasons. For a neurologically unaffected adult, the counseling challenge resembles that of a pathogenic LRRK2 or severe GBA1 variant, both of which carry elevated risk with incomplete penetrance. But prenatal detection is a different matter entirely. A carrier fetus could face a neurodevelopmental disorder, Parkinson’s disease in later life, or possibly no ITSN1-related neurological disorder at all, a range of outcomes so wide and so uncertain that it could make decisions about pregnancy continuation agonizing for prospective parents. Having confirmed the association between ITSN1 and Parkinson’s disease through the ROPAD replication, the Paris team argues that the field now faces an urgent need to resolve the questions of penetrance, expressivity, and inheritance pattern, not only to advance the science of neurodegeneration but to give families the accurate, honest information they will inevitably demand as this gene enters routine clinical testing.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk and inheritance

Article Title: Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Cogan, G., Tesson, C., Welment, L., Clot, F., LeGuern, E., Lanore, A., Dürr, A., Cormier-Dequaire, F., Debilly, B., Planes, M., Mangone, G., Lesage, S., & Brice, A. (2026). Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 236. https://doi.org/10.1038/s41531-026-01470-0

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01470-0

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, neurodevelopmental disorders, genetic counseling, reduced penetrance, Mendelian inheritance, LRRK2, GBA1

The story began to unfold in recent years when large-scale genetic studies pointed an unexpected finger at ITSN1. One analysis combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson’s Disease datasets found that heterozygous loss-of-function variants in the gene, meaning changes that cripple one of the two inherited copies, confer a substantially elevated risk of Parkinson’s disease. A second study described five patients from three families carrying distinct frameshift variants in ITSN1, documenting their clinical pictures in detail. A third effort, drawing on the UK Biobank, the AMP-PD cohort, and the All of Us program, reported a similar increase in risk and even supplied functional evidence from a fruit fly model, showing that the protein encoded by ITSN1, called Intersectin-1, interacts with alpha-synuclein, the sticky protein that clumps in the brains of Parkinson’s patients. What remained unclear was whether patients carrying these variants show a recognizable clinical signature.

To answer that question, the ROPAD team turned to their own trove of data. They analyzed 8,660 reportedly unrelated Parkinson’s disease patients recruited between April 2019 and August 2024, drawn from Europe (68 percent), North America (16 percent), Israel (10 percent), Turkey (4 percent), and South America (2 percent). Crucially, all of these patients had undergone exome or genome sequencing and had no relevant variants in known Parkinson’s genes. That exclusion criterion matters: the researchers removed anyone carrying a pathogenic or likely pathogenic variant in dominant Parkinson’s genes such as LRRK2, SNCA, VPS35, RAB32, or CHCHD2, anyone with two heterozygous or one homozygous pathogenic variant in recessive genes including PARK7, PINK1, and PRKN, and anyone with a pathogenic or risk-factor variant in GBA1, the most common genetic contributor to the disease. By stripping out known genetic explanations, the team could ask whether ITSN1 variants stand on their own as a risk factor.

As a comparison group, the researchers examined 210,657 exome- or genome-sequenced individuals from the CENTOGENE Biodatabank, people referred for routine diagnostic testing, healthy parents in trio analyses, or participants in other observational studies, none of whom had been referred for or diagnosed with Parkinson’s disease. Loss-of-function variants were defined rigorously as start-loss, stop-gain, stop-loss, splice-donor, splice-acceptor, or frameshift changes, identified through a validated in-house bioinformatic pipeline. The team then mined electronic case report forms for clinical details, including year of birth, sex, age at disease onset, age at diagnosis, age at enrollment, family history, and motor scores from a partial Unified Parkinson’s Disease Rating Scale examination.

The result was striking. Thirteen of the 8,660 patients, or 0.15 percent, carried heterozygous loss-of-function variants in ITSN1, compared with just 0.025 percent of the 210,657 comparison individuals. That difference translates into an odds ratio of 6.09, with a 95 percent confidence interval of 3.31 to 11.19 and a p-value of 1.34 times ten to the minus six, a level of statistical significance that is difficult to dismiss. The allele-level comparison tells the same story: the proportion of ITSN1 loss-of-function alleles in the Parkinson’s patients, 0.075 percent, is roughly six times higher than the proportion found in non-Finnish European individuals in the Genome Aggregation Database, the reference catalog that population geneticists use as a baseline for how common variants should be. The enrichment held against every other population in that database as well.

Perhaps most convincing is how neatly these numbers overlap with the earlier studies. The confidence interval from the ROPAD analysis largely overlaps those reported in the two prior association studies, which found odds ratios of 7.3 and 10.5 respectively. The carrier frequency of 0.15 percent in ROPAD matches the 0.15 percent reported in the deCODE-led meta-analysis and the 0.14 percent in the family study. Within the ROPAD cohort itself, ITSN1 loss-of-function variants rank as the sixth most common disease-relevant genetic finding, trailing only variants in GBA1, LRRK2, PRKN, SNCA, and GCH1. For a gene that was essentially invisible to Parkinson’s researchers a few years ago, that is a rapid ascent.

Digging into the variants themselves, the team identified 12 distinct ITSN1 loss-of-function changes among the 13 patients: four nonsense mutations, six frameshift variants, and two splice site changes. Eleven of the twelve appeared only once, and one, a small deletion designated c.2842_2843del, was found in two patients. When the researchers tested whether those two German patients were related, analysis of extended haplotypes found no evidence of close relatedness or a shared founder chromosome, suggesting the variant arose independently in each case. This pattern of largely private, one-off mutations contrasts sharply with the genetics of other dominant Parkinson’s genes, where a handful of recurrent variants, such as the famous LRRK2 G2019S change, account for most cases. It also hints that the mutational spectrum of ITSN1 resembles that of genes where virtually any disruption of the protein is harmful.

There is an intriguing twist. More than 40 distinct ITSN1 loss-of-function variants have already been reported in individuals with autism and neurodevelopmental disorders, and four of the variants found in the ROPAD patients had appeared in that literature. This overlap raises the possibility of pleiotropy, the phenomenon in which a single gene produces different outcomes depending on context. Intersectin-1 is a scaffolding protein involved in clathrin-mediated endocytosis, synaptic vesicle recycling, and actin and CDC42-related signaling, processes essential both for building neural circuits during development and for maintaining them across a lifetime. Losing one functional copy, a state called haploinsufficiency, might disturb neurodevelopmental circuitry in childhood or undermine neuronal maintenance later in life. Which outcome prevails may depend on genetic modifiers, the residual expression produced by splice-altering variants, environmental stressors, and other factors scientists have yet to untangle.

On the clinical side, the ROPAD analysis found that patients carrying ITSN1 variants look, in most respects, like ordinary Parkinson’s patients. The male-to-female ratio, the proportion with a positive family history, the age at diagnosis, the age at enrollment, and the disease duration all failed to differ significantly between carriers and non-carriers. A multiple linear regression of motor scores adjusted for disease duration also found no significant difference, though the p-value of 0.075 leaves open the possibility of a subtle effect. Interestingly, the two earlier large-cohort studies did report significantly younger ages at onset among carriers, with mean or median onsets in the early sixties versus around seventy in non-carriers. The ROPAD cohort as a whole skews young, with a mean and median onset of 55 years, which likely explains why the same signal did not emerge here. Notably, the median onset of 53 years among ROPAD carriers is comparable to the 47-year average onset in the five family-study patients, and one ROPAD participant carried both an ITSN1 deletion and a mild GBA1 variant, a combination the researchers excluded from their main analysis because the GBA1 change may have modified her disease risk, echoing what has been documented in people carrying both LRRK2 and GBA1 variants.

Taken together, the findings cement ITSN1 as a genuine Parkinson’s disease gene, one that produces a form of the illness clinically indistinguishable from idiopathic disease. The authors propose the designation PARK-ITSN1 for this genetic entity and call for further research into its natural history and treatment responses, questions that will matter as genetic testing becomes routine and as pharmaceutical companies design trials stratified by genotype. The study also carries a broader lesson about the power of deeply curated clinical and genetic datasets: when a diagnostic laboratory pairs sequencing with systematic phenotyping across thousands of patients, even vanishingly rare risk factors, present in fewer than two people per thousand, can be detected, validated, and connected to the biology of one of the world’s most common neurodegenerative diseases.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk in the ROPAD cohort

Article Title: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Ganoza, C. A., Westenberger, A., Paul, J. J., Curado, F., Somerville, E. N., Rennecke, J., Bauer, P., & Beetz, C. (2026). Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 237. https://doi.org/10.1038/s41531-026-01562-x

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01562-x

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, Intersectin-1, neurodegeneration, exome sequencing, age at onset, GBA1, pleiotropy

The disorder in question is cerebral cavernous malformation, or CCM, a condition in which clusters of abnormally dilated capillary channels form in the brain and spinal cord. These fragile vessels lack the normal structural support of healthy capillaries, making them prone to leakage and bleeding. Some people carry the lesions for life without ever knowing they have them, while others experience seizures, focal neurological deficits, debilitating headaches, or catastrophic intracranial hemorrhage. When the condition runs in families, it follows an autosomal dominant inheritance pattern, meaning a child of an affected parent has a fifty percent chance of inheriting the predisposition. Three genes account for the overwhelming majority of genetically confirmed familial cases: KRIT1 (also known as CCM1), CCM2, and PDCD10, with KRIT1 variants responsible for the largest share.

The new report centers on a fourteen-year-old boy who arrived at a pediatric neurology clinic after a focal epileptic seizure marked by numbness in his left arm. His medical history contained an unusual clue. Five months earlier, surgeons had removed a painful, progressively enlarging mass from his right parietal scalp—a lesion that had been palpable for roughly two years before accelerating in growth. Skull radiography and bone-window computed tomography revealed a well-circumscribed expansile lesion of the parietal bone with radiating trabecular striations, a classic spoke-wheel pattern pointing to a calvarial intraosseous hemangioma. Magnetic resonance imaging confirmed strong contrast enhancement of the diploic lesion, and histopathological examination of the resected bone specimen was compatible with hemangioma.

But the skull mass was only the beginning. Susceptibility-weighted imaging, a magnetic resonance sequence exquisitely sensitive to the blood breakdown products that accumulate in cavernous malformations, revealed multiple small punctate hypointense foci scattered throughout the cerebral parenchyma, along with bilateral lesions in the cerebellum. Spinal magnetic resonance imaging then uncovered a cervical intramedullary cavernous malformation, appearing as a central hyperintense core wrapped in a dark rim of hemosiderin—the iron-containing residue of prior microbleeds. Together, the multifocal brain and spinal findings strongly suggested a familial cavernous malformation syndrome rather than isolated sporadic disease.

The family history deepened the suspicion. The boy’s father had died suddenly at forty-one years of age from an intracerebral hemorrhage, a catastrophic event entirely consistent with an undiagnosed cavernous malformation bleed. Because the father was deceased, no genetic material was available to confirm his status, but the clinical picture weighed heavily in the investigators’ reasoning. Prompted by the combination of multifocal lesions, spinal involvement, and the fatal paternal hemorrhage, the team turned to whole-exome sequencing to search for a genetic culprit.

Sequencing delivered a clear answer. The boy carried a heterozygous duplication designated NM_004912.4: c.2dup in the KRIT1 gene—a single duplicated nucleotide at the second position of the coding sequence, directly disrupting the canonical translation initiation codon. The variant is predicted to trigger a frameshift from the very first coding codon, generating a premature termination signal at amino acid thirty-one, denoted p.(Met1IlefsTer31). The consequence is stark: the truncated protein would lack all major functional domains, including the ankyrin repeats, the FERM domain, the PDZ-binding motif, and the C-terminal regions that allow KRIT1—whose protein product is known as malcavernin—to stabilize endothelial cell junctions. Under current American College of Medical Genetics and Genomics criteria, the variant earned a likely pathogenic classification on the strength of four lines of evidence: the predicted loss-of-function effect in a gene where such loss is an established disease mechanism, its complete absence from population databases such as gnomAD, a phenotype highly specific to familial CCM, and clean segregation within the family. No pathogenic variants were found in CCM2 or PDCD10.

Segregation analysis revealed the variant’s reach. The proband’s sixteen-year-old brother, despite being entirely free of seizures, headaches, or any neurological symptoms, carries the identical variant—and brain magnetic resonance imaging showed multiple cavernous malformations in his parenchyma, though his spinal cord appeared uninvolved. Their mother, clinically healthy, does not carry the variant, which fits with the father being the presumed source of the mutation. A structured search of the medical literature and variant databases, including PubMed, ClinVar, and the Human Gene Mutation Database, failed to identify any previously reported individual or family carrying KRIT1 c.2dup or a closely related translation-initiation frameshift variant, making this the first documentation of the change.

The molecular biology underlying KRIT1-associated disease helps explain why the variant is so consequential. KRIT1 functions within the Rap1–KRIT1–CCM2 signaling complex, a molecular apparatus that maintains the integrity of endothelial tight junctions and restrains vascular permeability. Pathogenic variants typically cause disease through haploinsufficiency—one working copy of the gene is simply not enough to keep the vascular lining stable. Variants that sabotage the translation start site are particularly efficient at abolishing protein production, and previously reported initiation-region and early truncating KRIT1 variants, such as c.1A>G, c.143dup, c.152_155del, and several nonsense changes, all converge on the same mechanism: disrupted translation, premature truncation, or nonsense-mediated mRNA decay that eliminates the faulty transcript. The c.2dup variant stands out because it simultaneously destroys the initiation codon and introduces an immediate frameshift, a double hit predicted to eliminate functional protein entirely.

Perhaps the most clinically instructive aspect of the family is the striking variability among its members. One sibling lives with controlled epilepsy, intermittent headaches, and a history of an unusual skull tumor; the other is completely asymptomatic yet harbors multiple brain lesions visible only on susceptibility-weighted sequences; their father likely died of the condition’s most feared complication. This spectrum—from silent radiological disease to fatal hemorrhage within a single household—underscores a persistent limitation of genetic medicine: knowing the genotype does not reliably predict clinical severity, hemorrhagic risk, or long-term outcome in familial CCM. Age-dependent penetrance and variable expression complicate counseling and make lifelong surveillance essential even for people who feel perfectly well.

Management in the reported family followed current best practice, which remains largely phenotype-driven. The proband’s seizures responded well to levetiracetam, leaving him seizure-free for six months, while his intracranial lesions were placed under radiological surveillance rather than surgical treatment. His asymptomatic brother likewise required only structured clinical and radiological monitoring. Surgery is generally reserved for medically refractory epilepsy, recurrent hemorrhage, progressive neurological deficits, or readily accessible symptomatic lesions. Interestingly, the authors addressed the boy’s calvarial hemangioma directly, concluding that its coexistence with familial CCM is almost certainly incidental. Under the International Society for the Study of Vascular Anomalies classification, hemangiomas are proliferative vascular tumors, whereas cavernous malformations are slow-flow malformations of vascular morphogenesis—fundamentally different entities. A recent cohort study of 257 pediatric patients carrying 786 cerebral and 14 spinal cavernous malformations reported no concomitant hemangiomas, reinforcing the interpretation that the two findings in this boy are unrelated.

The authors acknowledge limitations, including the absence of genetic data from the deceased father, the lack of confirmatory Sanger sequencing—mitigated by exceptionally deep sequencing coverage exceeding 110-fold with more than 97 percent of target regions covered at twentyfold or greater—relatively short follow-up, and the lack of functional validation studies such as transcript or protein analyses. Even so, the convergence of high-quality sequencing, familial segregation, characteristic neuroimaging, and standardized variant interpretation makes a compelling case. The broader message for clinicians and families is unambiguous: integrating molecular diagnostics, cascade genetic testing of at-risk relatives, and susceptibility-weighted magnetic resonance imaging can identify silent carriers of KRIT1 variants before symptoms appear, opening a window for counseling, risk stratification, and monitoring that could one day prevent the kind of sudden, fatal hemorrhage that struck this family’s father.

Subject of Research: Familial cerebral cavernous malformation caused by a novel KRIT1 translation initiation-region frameshift variant

Article Title: Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant

Article References: Yayıcı Köken, Ö., Yanartaş, M. S., Aygün, H., Ceylan, A. C., Karaali, K., & Kazan, M. S. (2026). Pediatric Familial Cerebral Cavernous Malformation Associated With a Novel KRIT1 Initiation‐Region Frameshift Variant. Molecular Genetics & Genomic Medicine, 14(9), Article e70304. https://doi.org/10.1002/mgg3.70304

Image Credits: AI Generated

DOI: 10.1002/mgg3.70304

Keywords: cerebral cavernous malformation, KRIT1, malcavernin, frameshift variant, whole-exome sequencing, familial CCM, susceptibility-weighted imaging, pediatric neurology, epilepsy, intracerebral hemorrhage, genetic testing, haploinsufficiency

The brake in question sits in the 5ʹ untranslated region, the stretch of RNA that precedes the protein-coding sequence of a transcript. Although it does not encode protein, this region exerts powerful control over how efficiently ribosomes translate the main message. One of its most potent repressive elements is the upstream open reading frame, or uORF, a short alternative reading frame that begins at an upstream start codon and diverts ribosomes away from the true protein. When a ribosome initiates at a uORF and terminates before reaching the main coding sequence, that translation event is wasted. Genes carrying strong uORFs therefore tend to make less protein than their mRNA abundance would predict, and in a haploinsufficient disease that shortfall can tip an individual over the threshold of clinical disease.

Earlier proposals for exploiting this biology focused on steric-block antisense oligonucleotides, synthetic DNA-like molecules that bind to the uORF start codon and physically obstruct ribosome initiation. The approach has shown promise for a handful of specific genes, but its broad applicability has been debated, because the geometry of each uORF differs and blocking initiation is not always feasible or effective. The Oxford-led team, working with colleagues at the International Centre for Genetic Engineering and Biotechnology in Trieste, the University of Exeter and industry partners, pursued a different tactic. Instead of masking the uORF, they asked whether the exon that contains it could be spliced out of the mature mRNA altogether, converting an inhibitory 5ʹUTR into a shorter, permissive one through the cell’s own RNA processing machinery.

To test how widely such an approach might apply, the researchers systematically screened human transcript annotations. Using MANE transcript definitions, the matched annotations agreed upon by NCBI and EMBL-EBI as the definitive reference set for each human gene, they catalogued exons located entirely within 5ʹ untranslated regions whose removal would preserve the reading frame and regulatory logic of the transcript. This analysis yielded 2,210 potentially skippable 5ʹUTR exons. The critical next step was to determine which of those exons actually contain functional uORF start codons, since a start codon annotated in the genome is only repressive if ribosomes genuinely engage with it in living cells.

To make that determination, the team mined ribosome profiling data generated from 13 human tissues and cell lines, including brain, heart and skeletal muscle. Ribosome profiling captures snapshots of ribosome positions across the transcriptome, allowing researchers to distinguish start codons that are actively used from those that are silent. Applying this filter, the researchers identified 1,056 skippable 5ʹUTR exons harbouring translated uORF start codons. Crucially, 79 of these exons sit in genes already classified as haploinsufficient monogenic disease genes in expert-curated resources such as ClinGen, the Gene Curation Coalition and Gene2Phenotype. In other words, a defined, immediately clinically relevant target list already exists, and the authors suggest it could serve as a roadmap for precision medicines across dozens of rare disorders.

From that list the team prioritised six candidate exons in genes linked to neurodevelopmental disorders, a therapeutic area where haploinsufficiency is common and where the blood–brain barrier complicates conventional protein replacement. They constructed dual luciferase reporter assays in which the native 5ʹUTR of each target gene drives a measurable enzyme, then compared translation when the candidate exon was removed. For four of the six genes—CTCF, GRIN2B, KRIT1 and TSC1—skipping the target exon significantly boosted downstream protein production, with increases ranging from 1.4-fold to 5.5-fold. That magnitude matters, because many haploinsufficient disorders are thought to respond to even modest restoration of gene dosage, and a twofold increase in protein output would be transformative for conditions in which patients carry essentially half of the normal complement.

A key mechanistic question was whether the benefit came from removing the uORF itself or from other regulatory elements embedded in the skipped exons, such as RNA structures, microRNA sites or RNA-binding protein motifs that might independently suppress translation. To disentangle these effects, the researchers created reporters in which only the uORF start codons were mutated, leaving the rest of the exon sequence intact. Removing the start codons alone increased translation to comparable or even greater levels, between 1.4-fold and 7.9-fold, indicating that the uORF is the dominant repressive element in these exons. For TSC1, the gene mutated in a subset of tuberous sclerosis complex cases, the team went further and showed that multiple uORFs act additively, with each additional upstream reading frame further depressing protein output from the main coding sequence.

The most clinically significant experiment involved splice-switching antisense oligonucleotides, shortened to SSOs. These chemically modified oligonucleotides bind pre-mRNA sequences such as splice donor or acceptor sites and trick the cellular splicing machinery into excluding a chosen exon. The researchers designed SSOs against the prioritised TSC1 5ʹUTR exon and demonstrated that treatment induced the intended exon skipping in cells and up-regulated levels of the endogenous TSC1 protein, produced from the cell’s own genomic copy rather than from a reporter construct. This is the decisive proof of concept: it shows that the strategy works not just on engineered sequences but on the authentic genomic context of a real disease gene, using a drug modality—antisense oligonucleotides—that already has an established clinical track record in spinal muscular atrophy, Duchenne muscular dystrophy and other conditions.

Splice-switching antisense technology brings genuine advantages for rare disease. Because ASOs can be designed rationally from the genomic sequence, a bespoke candidate can be developed quickly for an individual gene or even an individual patient, an approach that has already produced landmark personalised treatments for ultra-rare genetic conditions. The Oxford team’s systematic catalogue of 1,056 uORF-bearing skippable exons effectively converts that bespoke potential into a scalable pipeline: identify the haploinsufficient gene, check whether it carries a skippable 5ʹUTR exon with an active uORF, design an SSO, and titrate protein output back toward normal. The authors argue that their findings support the broad application of 5ʹUTR exon skipping as a general therapeutic mechanism for upregulating protein production from clinically relevant haploinsufficient genes.

Important caveats remain before patients benefit. The four of six prioritised exons that did not respond uniformly remind the field that uORF architecture varies, and that some 5ʹUTR exons may contain activating elements whose loss could be harmful. Delivery to the brain and other tissues, dose control, and the safety of chronically boosting dosage of tumour-suppressor-class genes such as TSC1 and CTCF will all require careful preclinical and clinical evaluation. The translational potential has nonetheless attracted commercial interest: several of the authors hold patents on uORF-targeting technologies and exon-skipping approaches licensed to a University of Oxford spin-out, and the work draws on genomic data from hundreds of thousands of participants in the UK’s National Genomic Research Library. If the approach clears those hurdles, the humble untranslated region—a stretch of RNA long treated as a footnote to the genetic code—may become one of the most promising drug targets in rare disease medicine.

Subject of Research: Using splice-switching antisense oligonucleotides to skip uORF-containing 5ʹ untranslated region exons and upregulate protein expression from haploinsufficient disease genes.

Article Title: Modulating splicing in 5ʹ untranslated regions to treat rare haploinsufficient disease

Article References: Beer Wells, E. S., De Conti, L., Kim, H. C., Rohani, N., Chundru, K., Svrzikapa, N., McClorey, G., Watts, L. M., Dawes, R., Chen, Y., Martin-Geary, A. C., Griffiths, M. J., Scott, S., Bamford, R. A., Wood, M. J., Roberts, T. C., Mill, J., Wright, C. F., Baralle, M., … Whiffin, N. (2026). Modulating splicing in 5ʹ untranslated regions to treat rare haploinsufficient disease. Genome Medicine. https://doi.org/10.1186/s13073-026-01773-0

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01773-0

Keywords: rare disease, haploinsufficiency, antisense oligonucleotides, 5ʹ untranslated region, upstream open reading frames, splicing, therapeutic upregulation, TSC1, CTCF, GRIN2B, neurodevelopmental disorders, Genome Medicine